Assertio Holdings, Inc. (ASRT)
NASDAQ: ASRT · Real-Time Price · USD
0.768
-0.017 (-2.12%)
At close: Dec 5, 2025, 4:00 PM EST
0.752
-0.015 (-2.01%)
After-hours: Dec 5, 2025, 7:06 PM EST
Assertio Holdings Revenue
Assertio Holdings had revenue of $49.46M in the quarter ending September 30, 2025, with 69.36% growth. This brings the company's revenue in the last twelve months to $137.35M, up 9.22% year-over-year. In the year 2024, Assertio Holdings had annual revenue of $124.96M, down -17.83%.
Revenue (ttm)
$137.35M
Revenue Growth
+9.22%
P/S Ratio
0.54
Revenue / Employee
$2,368,172
Employees
58
Market Cap
73.87M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 124.96M | -27.11M | -17.83% |
| Dec 31, 2023 | 152.07M | -4.17M | -2.67% |
| Dec 31, 2022 | 156.23M | 45.22M | 40.73% |
| Dec 31, 2021 | 111.01M | 2.94M | 2.72% |
| Dec 31, 2020 | 108.08M | -121.45M | -52.91% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ASRT News
- 25 days ago - Assertio Holdings, Inc. (ASRT) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 25 days ago - Assertio Reports Third Quarter 2025 Financial Results - Business Wire
- 5 weeks ago - Assertio Announces Leadership Transition - GlobeNewsWire
- 2 months ago - DEADLINE NEXT WEEK: Berger Montague Advises Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) Investors to Contact the Firm Before September 24, 2025 - GlobeNewsWire
- 2 months ago - Assertio Presents First-Ever Real-World Study Showing Patient Experience with SYMPAZAN® (clobazam) Oral Film, CIV - GlobeNewsWire
- 3 months ago - Assertio to Present New Data from Real-World Evidence Study of SYMPAZAN® at upcoming 150th Annual Meeting of the American Neurological Association - GlobeNewsWire
- 3 months ago - Assertio to Participate in the HC Wainwright and Lake Street Conferences in September 2025 - GlobeNewsWire
- 4 months ago - Assertio Holdings, Inc. (ASRT) Q2 2025 Earnings Call Transcript - Seeking Alpha